Influenza Vaccines for the World

19-21 April 2017, CHUVUniversity of Lausanne, Lausanne, Switzerland

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Wednesday 19th April 2017

07.50-08.50
Arrival & Registration & Poster Set-Up

08.50-09.00
Welcome to Lausanne and Opening Remarks
John Oxford (Queen Mary College, University of London, London, UK)

SESSION 1:
OPENING PLENARY SESSION

Moderator: John Oxford (Queen Mary College, University of London, London, UK)

09.00-09.30
‘The Global Action Plan (GAP) for influenza vaccines 10 years on’
Gary Grohmann, Erin Sparrow, Martin Friede and Claudia Nannei (WHO, Geneva, Switzerland)

09.30-10.00
‘Treating the host response to emerging virus diseases: Lessons learned from influenza and ebola, and implications for global health and security’
David Fedson (Independent Consultant, Sergy Haut, France)

10.00-10.30
‘The challenge of vaccinating healthcare workers against influenza’
Jonathan Van Tam (University of Nottingham, Nottingham, UK)

10.30-11.00
Coffee Break & Posters Set-Up

SESSION 2:
PLENARY II

Moderator: Helen Bright (MedImmune Ltd, Liverpool, Merseyside, UK)

11.00-11.30
‘Infection in quarantined volunteers for basic studies of viruses, vaccines and antibody therapies’
John Oxford (Queen Mary College, University of London, London, UK)

11.30-12.00
‘The past and future of LAIV’
Timo Vesikari (University of Tampere, Tampere, Finland)

12.00-12.30
‘Beyond hemagglutinin for flu vaccines: A new analytical platform for tracking HA, NA, M1 and NP’
Kathy Rowlen (InDevR Inc., Boulder, Colorado, USA)

12.30-13.30
Lunch Break & Posters

SESSION 3:
INFLUENZA VIRUSES

Moderator: Ted Ross (University of Georgia, Athens, Georgia, USA)

13.30-14.00
‘Improvement of influenza candidate vaccine viruses’
Othmar G. Engelhardt (NIBSC, South Mimms, Potters Bar, Hertfordshire, UK)

14.00-14.20
‘Human virus challenge models, from one century to the next: What have we learned?
Rob Lambkin-Williams (hVIVO Ltd, London, UK)

14.20-14.40
‘Ferret models to study vaccine strategies against influenza’
Koert Stittelaar1, Leon de Waal1, Geert van Amerongen1, Marie Pohl1, Edwin Veldhuis Kroeze1 and Albert Osterhaus1,2,3 (1 Viroclinics Biosciences B.V., Rotterdam, The Netherlands; 2 Artemis One Health, Utrecht, The Netherlands; 3 University of Veterinary Medicine, Hannover, Germany)

14.40-15.00
‘COBRA HA induced hemagglutination-inhibition antibodies against a panel of H3N2 influenza antigenic variants’
James D. Allen1, Terianne M. Wong1, Anne-Gaelle Bebin-Blackwell1, Donald M. Carter1, Timothy Alefantis2, Joshua DiNapoli2, Harold Kleanthous2 and Ted M. Ross1 (1 University of Georgia, Athens, Georgia, USA; 2 Sanofi-Pasteur, Inc., Discovery Research, Cambridge, Massachusetts, USA)

15.00-15.20
‘Emergence and spread of antigenic variants for H3N2 influenza A viruses: Uncertainty and rapidity’
Xiu-Feng Wan, Lei Han, Lei Li and Tong Zhang (College of Veterinary Medicine, Mississippi State University, Mississippi, USA)

15.20-15.40
‘A novel amphibian innate immune mediator is virucidal for human influenza viruses’
Joshy Jacob (Emory University, Atlanta, Georgia, USA)

Tea Break & Posters

SESSION 4:
INFLUENZA VACCINES

Moderator: Jonathan Van Tam (University of Nottingham, Nottingham, UK)

16.00-16.20
‘The rationale for quadrivalent influenza vaccines’
Dirk Poelert (GlaxoSmithKline, Wavre, Belgium)

16.20-16.40
‘A role for DNA immunization in preventing influenza infection’
Grant Weaver, Shixia Wang, and Shan Lu (University of Massachusetts Medical School, Worcester, Massachusetts, USA)

16.40-17.00
‘Pan-influenza A protection from group 1 and 2 viruses provided by X-31 cold-adapted live attenuated influenza vaccine’
Yo Han Jang1, Joo Young Kim2, Young Ho Byun1, Ahyun Son1, Yoon Jae Lee1, Jun Chang2 and Baik Lin Seong1,3 (1 Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea; 2 Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, South Korea; 3 Vaccine Translational Research Center, Yonsei University, Seoul, South Korea)

17.00-17.20
‘A novel influenza vaccine targeting an epitope of limited variability’
Craig P. Thompson1,2, José Lourenço1, Mathew Edmans1,2, Kreepa Kooblall3,
Duncan Palmer1, George Carnell4, Daniel O’Connor5, Thomas Bowden6, Andrew Pollard5, Nigel J. Temperton4, Teresa Lambe2, Sarah Gilbert2 and Sunetra Gupta1 (1 Department of Zoology, University of Oxford, UK; 2 The Jenner Institute Laboratories, University of Oxford, UK; 3 Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK; 4 Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, UK; 5 Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK; 6 Division of Structural Biology, University of Oxford, UK)

17.20-17.40
‘A “magic” sequence to increase immunogenicity of recombinant prokaryotic and eukaryotic antigens’
I. Legastelois1, I. Peubez1, S. Margot1, S. Buffin1, H. Boukhebza1, A. Pilloud1, C. Pion1, V. Courtois1, L. Potdevin1, S. Commandeur1, V. Marin1, M.C. Bernard1, P. Dinadayala1, D. Poncet1, R. Sodoyer1,2 and J. Haensler1 (1 Research and Development, Sanofi Pasteur, Marcy L’toile, France; 2 OTECI, Lyon, France)

17.40-18.00
‘Regulatory T cell epitope deletion enhances H7N9 influenza vaccine immunogenicity’
Oreda Boussadia1, Annie De Groot1,2, Lenny Moise1,2, Rui Liu2, Bradford C. Lefoley3, Rayleigh Chan3,4, Manabu Ato5, Yoshimasa Takahashi5, Arnone Nithichanon5,6, Ted M. Ross3 and William Martin1 (1 EpiVax, Inc., Providence, Rhode Island, USA; 2 Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island, USA; 3 Center for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA; 4 University of British Columbia, Vancouver, British Columbia, Canada; 5 National Institute of Infectious Diseases, Tokyo, Japan; 6 Khon Kaen University, Khon Kaen, Thailand)

18.00-19.00
IVW 2017 Welcome Drinks Reception & Posters

 

IVW 2017 Delegates

Login details will be supplied after you have registered for the event.


IVW 2017 Sponsors

  • hVIVO
  • Vaxart
  • FluConsult
  • MedImmune
  • Nanopass
  • InDevR
  • Inovio
  • Eurocine Vaccines
  • Protein Sciences
  • Biondvax
  • VisMederi
  • Sanofi Pasteur
  • Fraunhofer
  • APACI
  • Janssen
  • ISIRV
  • MedicaGo

IVW 2017 Downloads

IVW 2017 Leaflet

IVW 2017 Mailing List

Name
E-mail Address
What is 3+2-1?